Research programme: antibacterials - Galapagos/LEO Pharma
Latest Information Update: 15 Apr 2014
At a glance
- Originator Galapagos NV; LEO Pharma
- Developer BioFocus DPI
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 15 Apr 2014 Discontinued - Preclinical for Bacterial infections in Belgium (unspecified route)
- 15 Apr 2014 Discontinued - Preclinical for Bacterial infections in Denmark (unspecified route)
- 31 Mar 2014 BioFocus DPI has been acquired by Charles River Laboratories